Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 58 min ago
Peer-reviewedLicence not statedMed (New York, N.Y.)

Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trials

  • Jose A. Santiago1,2
  • Olivier Rascol3
  • Tom Foltynie4,5
  • Wassilios G. Meissner6,7
  • Judith A. Potashkin8
  • Jean C. Gutierrez-Silva1
  • Mohammad Nafeli Shahrestani2
  • Yusen Wu2
  • Tatjana Rundek2
  • Ihtsham Ul Haq2
8 affiliations
  1. 1NeuroHub Analytics, LLC, Chicago, IL, USA
  2. 2Department of Neurology and Evelyn F. McKnight Brain Institute, University of Miami Miller School of Medicine, Miami, FL, USA
  3. 3Department of Neurosciences and Clinical Pharmacology, Clinical Investigation Center 1436, NeuroToul Center of Excellence, and NS-Park/FCRIN Network, University of Toulouse, University Hospital of Toulouse, INSERM, Toulouse, France
  4. 4University College London (UCL), Institute of Neurology, London, UK
  5. 5Movement Disorders, National Hospital for Neurology and Neurosurgery, London, UK
  6. 6CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, Bordeaux, France.
  7. 7Univ. de Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France
  8. 8Center for Neurodegenerative Disease and Therapeutics, Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
Read full textDOICite

Related

  1. Disease-specific intrinsic frequency alterations in electroencephalographic signals of Alzheimer’s disease, frontotemporal dementia, and Parkinson’s disease
    Ryohei Fukuma, Yoshinobu Kawahara, Okito Yamashita +3
    Communications MedicinePeer-reviewedCC BY-NC-ND 4.0Full textNeuroscienceCrossref
  2. Cross-disorder Learning of Imaging-derived Joint Mophometric Markers in Alzheimer's and Parkinson's Diseases
    Yuji Zhao, Boris Gutman
    arXivPreprintarXiv licenceFull textBioinformatics & computational biologyNeurosciencearXiv
  3. The Use of Statins in Parkinson's and Alzheimer's Disease: A 2021–2025 State‐of‐the‐Art Review of Clinical and Preclinical Evidence
    Luigi Maria Chiatto, Lucia Buccarello, Giuseppe Carota +5
    Pharmacology Research & PerspectivesPeer-reviewedCC BY5 citedNeuroscienceOpenAlex
  4. In Vitro Screening of Sargassum spp. Ethanolic Extracts for Antioxidant Activity and Inhibition of Disease-Associated Enzymatic Targets Related to Diabetes, Alzheimer's Disease, and Parkinson's Disease.
    Md Yousof Ali, Se Eun Park, Hyun Ah Jung +1
    International journal of molecular sciencesPeer-reviewedCC BYFull textEcologyEurope PMC
  5. Integrated-omics endotyping of infants with rhinovirus bronchiolitis and risk of childhood asthma
    Y. Raita, Jr. Camargo, Y. A. Bochkov +6
    Journal of Allergy and Clinical ImmunologyPeer-reviewedLicence not stated69 citedMicrobiologyHAL

Cite

BibTeXRIS
BibTeX
@article{santiago2026metabolic,
  title = {{Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trials}},
  author = {Jose A. Santiago and Olivier Rascol and Tom Foltynie and Wassilios G. Meissner and Judith A. Potashkin and Jean C. Gutierrez-Silva and Mohammad Nafeli Shahrestani and Yusen Wu and Tatjana Rundek and Ihtsham Ul Haq},
  journal = {Med (New York, N.Y.)},
  year = {2026},
  month = oct,
  doi = {10.1016/j.medj.2026.101336},
  url = {https://doi.org/10.1016/j.medj.2026.101336},
}
RIS
TY  - JOUR
TI  - Metabolic endotyping for mechanism-informed Alzheimer’s and Parkinson’s disease trials
AU  - Jose A. Santiago
AU  - Olivier Rascol
AU  - Tom Foltynie
AU  - Wassilios G. Meissner
AU  - Judith A. Potashkin
AU  - Jean C. Gutierrez-Silva
AU  - Mohammad Nafeli Shahrestani
AU  - Yusen Wu
AU  - Tatjana Rundek
AU  - Ihtsham Ul Haq
PY  - 2026
DA  - 2026/10/30
JO  - Med (New York, N.Y.)
DO  - 10.1016/j.medj.2026.101336
UR  - https://doi.org/10.1016/j.medj.2026.101336
SN  - 2666-6359
SN  - 2666-6340
ER  -